250 related articles for article (PubMed ID: 21794764)
1. [Certolizumab pegol].
Delgado Frías E; Díaz González JF
Reumatol Clin; 2011 Mar; 6S3():S7-11. PubMed ID: 21794764
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
3. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
Meroni PL; Valesini G
BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab pegol in rheumatoid arthritis: current update.
Fechtenbaum M; Md Yusof MY; Emery P
Expert Opin Biol Ther; 2014 Jun; 14(6):841-50. PubMed ID: 24654999
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
[TBL] [Abstract][Full Text] [Related]
7. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
Aletaha D
BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
[No Abstract] [Full Text] [Related]
8. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation of certolizumab pegol.
Ferrante M; Vermeire S; Rutgeerts PJ
Expert Opin Drug Saf; 2014 Feb; 13(2):255-66. PubMed ID: 24156537
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.
Deeks ED
Drugs; 2013 Jan; 73(1):75-97. PubMed ID: 23338540
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
Patel AM; Moreland LW
Expert Rev Clin Immunol; 2010 Nov; 6(6):855-66. PubMed ID: 20979550
[TBL] [Abstract][Full Text] [Related]
15. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
Ramiro S; van Tubergen AM; Landewé RB
Expert Rev Clin Immunol; 2010 Sep; 6(5):713-20. PubMed ID: 20828279
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
[TBL] [Abstract][Full Text] [Related]
17. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs.
Harigai M; Takamura A; Atsumi T; Dohi M; Hirata S; Kameda H; Nagasawa H; Seto Y; Koike T; Miyasaka N
Mod Rheumatol; 2013 Mar; 23(2):284-96. PubMed ID: 22588312
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab: efficacy and safety profile of a novel pegylated TNF-alpha blocking agent.
Lubrano E; Spadaro A
Acta Biomed; 2011 Apr; 82(1):26-34. PubMed ID: 22069953
[TBL] [Abstract][Full Text] [Related]
19. Certolizumab pegol: in rheumatoid arthritis.
Duggan ST; Keam SJ
BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol for the treatment of rheumatoid arthritis.
Horton S; Walsh C; Emery P
Expert Opin Biol Ther; 2012 Feb; 12(2):235-49. PubMed ID: 22165979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
